Literature DB >> 15699374

Detection of serum reverse transcriptase activity in patients with ALS and unaffected blood relatives.

A J Steele1, A Al-Chalabi, K Ferrante, M E Cudkowicz, R H Brown, J A Garson.   

Abstract

BACKGROUND: Retroviral involvement in the etiology of sporadic ALS has been suspected for several years since the recognition that both murine and human retroviruses can cause motor neuron disease-like syndromes. In a pilot study, an increased prevalence of a retroviral marker (reverse transcriptase [RT] activity) was demonstrated in the serum of British patients with ALS. The current investigation was designed to confirm and extend these findings in a geographically distinct patient cohort under blinded testing conditions.
METHODS: A highly sensitive product-enhanced RT assay was employed to test coded sera obtained from 30 American patients with sporadic ALS and from 14 of their blood relatives, 16 of their spouses, and 28 nonrelated, nonspousal control subjects.
RESULTS: Serum RT activity was detected in a higher proportion of ALS patients (47%) than in non-blood-related controls (18%; p = 0.008). The prevalence of RT activity in the serum of spousal controls (13%) was similar to that in other non-blood-related controls. Unexpectedly, the prevalence of serum RT activity in blood relatives of ALS patients (43%) approached that in the ALS patients themselves.
CONCLUSIONS: These results confirm that patients with ALS have a significantly higher prevalence of serum reverse transcriptase (RT) activity than that seen in unrelated control subjects. The finding of a similarly increased prevalence in blood relatives of ALS patients raises the possibility that the observed RT activity might be due to an inherited endogenous retrovirus.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15699374     DOI: 10.1212/01.WNL.0000150899.76130.71

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  37 in total

1.  Identification of active loci of a human endogenous retrovirus in neurons of patients with amyotrophic lateral sclerosis.

Authors:  Renée Douville; Jiankai Liu; Jeffrey Rothstein; Avindra Nath
Journal:  Ann Neurol       Date:  2011-01       Impact factor: 10.422

Review 2.  The Retrotransposon storm and the dangers of a Collyer's genome.

Authors:  Josh Dubnau
Journal:  Curr Opin Genet Dev       Date:  2018-05-08       Impact factor: 5.578

Review 3.  Human endogenous retrovirus-K (HML-2): a comprehensive review.

Authors:  Marta Garcia-Montojo; Tara Doucet-O'Hare; Lisa Henderson; Avindra Nath
Journal:  Crit Rev Microbiol       Date:  2018-10-14       Impact factor: 7.624

Review 4.  Endogenous retrovirus-K and nervous system diseases.

Authors:  Mamneet Manghera; Jennifer Ferguson; Renée Douville
Journal:  Curr Neurol Neurosci Rep       Date:  2014-10       Impact factor: 5.081

5.  HIV-associated motor neuron disease: HERV-K activation and response to antiretroviral therapy.

Authors:  Lauren N Bowen; Richa Tyagi; Wenxue Li; Tariq Alfahad; Bryan Smith; Mary Wright; Elyse J Singer; Avindra Nath
Journal:  Neurology       Date:  2016-09-24       Impact factor: 9.910

Review 6.  Retroviruses and amyotrophic lateral sclerosis.

Authors:  Tariq Alfahad; Avindra Nath
Journal:  Antiviral Res       Date:  2013-05-23       Impact factor: 5.970

Review 7.  Biomarkers in amyotrophic lateral sclerosis: facts and future horizons.

Authors:  Pierre-François Pradat; Michel Dib
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

8.  Familial aggregation of amyotrophic lateral sclerosis.

Authors:  Fang Fang; Freya Kamel; Paul Lichtenstein; Rino Bellocco; Pär Sparén; Dale P Sandler; Weimin Ye
Journal:  Ann Neurol       Date:  2009-07       Impact factor: 10.422

9.  Inhibition of HERV-K (HML-2) in amyotrophic lateral sclerosis patients on antiretroviral therapy.

Authors:  M Garcia-Montojo; S Fathi; G Norato; B R Smith; D B Rowe; M C Kiernan; S Vucic; S Mathers; R P A van Eijk; U Santamaria; M-L Rogers; A Malaspina; V Lombardi; P R Mehta; H-J Westeneng; L H van den Berg; A Al-Chalabi; J Gold; A Nath
Journal:  J Neurol Sci       Date:  2021-02-23       Impact factor: 3.181

Review 10.  Awakening the dark side: retrotransposon activation in neurodegenerative disorders.

Authors:  Elizabeth Ochoa Thomas; Gabbe Zuniga; Wenyan Sun; Bess Frost
Journal:  Curr Opin Neurobiol       Date:  2020-02-21       Impact factor: 6.627

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.